SCHEMBL4635281

SCHEMBL4635281

NC1C2CN(C(=O)c3ccc(-c4ccccc4)cc3)CC12

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.58
MAPK1 P28482 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.56
POLB P06746 3/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
SLC6A7 Q99884 2/20 0.53
ALDH1A1 P00352 3/20 0.52
FASN P49327 3/20 0.51
HTR2B P41595 1/20 0.51
TSHR P16473 4/20 0.50
TLR2 O60603 1/20 0.48
TLR1 Q15399 1/20 0.48
MGLL Q99685 2/20 0.48
HSD11B1 P28845 1/20 0.48
LMNA P02545 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386696 0.87 HPGD (0.62) HPGDMAPK1SMN1; SMN2POLBMEN1
SCHEMBL8158994 0.81 HPGD (0.64) HPGDMAPK1SMN1; SMN2POLBMEN1
SCHEMBL4635067 0.80 HSD11B1 (0.51) POLBMEN1KMT2AALDH1A1TLR2
SCHEMBL4635518 0.80 HSD17B10 (0.52) HPGDPOLBMEN1KMT2AALDH1A1
SCHEMBL4636574 0.80 PKM (0.56) HPGDMEN1KMT2AALDH1A1TLR2
SCHEMBL4635076 0.80 HSD11B1 (0.46) HPGDMEN1KMT2AALDH1A1HSD11B1
SCHEMBL15958971 0.80 PLA2G1B (0.67) HPGDMAPK1SMN1; SMN2POLBMEN1
SCHEMBL20067709 0.78 SMN1; SMN2 (0.65) HPGDMAPK1SMN1; SMN2POLBMEN1
SCHEMBL20067667 0.78 SMN1; SMN2 (0.65) HPGDMAPK1SMN1; SMN2POLBMEN1
SCHEMBL4636441 0.78 DPP4 (0.61) HPGDPOLBMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 HPGD 2646/4885MAPK1 1875/4885SMN1; SMN2 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.